Hormone therapy and venous thromboembolism among postmenopausal women

Frontiers of Hormone Research

Volumn 43, Issue , 2014, Pages 21-32

  Scarabin, Pierre Yves ^a  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RECOMBINANT HORMONE; THROMBIN;

ARTERY THROMBOSIS; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ESTROGEN THERAPY; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HIGH RISK POPULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MUTATION; OBESITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BREAST TUMOR; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); FEMALE; INTRADERMAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, CUTANEOUS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; POSTMENOPAUSE; PROGESTINS; RISK; VENOUS THROMBOEMBOLISM;

EID: 84911378666     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000360554     Document Type: Article

References (29)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
2. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY: Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-1231.
3. Olié V, Canonico M, Scarabin PY: Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010; 17: 457-463.
4. Canonico M, Plu-Bureau G, Scarabin PY: Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011; 70: 354-360.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
6. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM: Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-967.
7. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-1580.
8. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch M, Cyr MG, Gas M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR: Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772-780.
9. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW; WISDOM Group: Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 239.
10. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
11. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A: Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
12. Hoibraaten E, Abdelnoor M, Sandset PM: Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based casecontrol study. Thromb Haemost 1999; 82: 1218-1221.
13. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, et al: Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005; 3: 943-948.
14. Scarabin PY, Oger E, Plu-Bureau G; Estrogen and Thromboembolism Risk Study Group: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
15. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al: Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845.
16. Renoux C, Dell'Aniello S, Suissa S: Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemost 2010; 8: 979-986.
17. Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, et al: Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340-345.
18. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK; The Million Women Study Collaborators: Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012; 10: 2277-2286.
19. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A: The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11: 124-131.
20. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM: Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014; 174: 25-31.
21. Olie V, Canonico M, Scarabin PY: Postmenopausal hormone therapy and venous thromboembolism. Thromb Res 2011; 127(suppl 3):S26-S29.
22. Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY: Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011; 18: 1-5.
23. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M: Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
24. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al: Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671-1676.
25. Scarabin PY, Hemker HC, Clément C, Soisson V, Alhenc-Gelas M: Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause 2011; 18: 873-879.
26. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olie V, Scarabin PY: Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010; 17: 1122-1127.
27. Marjoribanks J, Farquhar C, Roberts H, Lethaby A: Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7:CD004143.
28. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012; 19: 257-271.
29. Tremollieres F, Brincat M, Erel CT, Gambacciani M, Lambrinoudaki I, Moen MH, Schenck-Gustafsson K, Vujovic S, Rozenberg S, Rees M; European Menopause and Andropause Society: EMAS position statement: managing menopausal women with a personal or family history of VTE. Maturitas 2011; 69: 195-198.